

# The 8th Biennial Congress of The Asian Neurogastroenterology and Motility Association

In conjunction with  
**Indonesian Digestive  
Disease Week**

vol

**3**

# Table of Content

Our Sponsors	3
Today's Agenda	4
Poster and Oral Presentation	5
Plenary Lecture	6
Symposium 10	7
Symposium 11	8
Symposium 12	8
Symposium 13	9
Symposium 14	10
Symposium 15	11
Symposium 16	11
Symposium 17	12
Symposium 18	13
Special Lecture 3	13
Special Lecture 4	14
What Do The Participants Say?	15
Pictures of DAY 3 IDDW ANMA 2025	16
Winner Announcement	17

## Committee and Credits

### Pimpinan Produksi

Nabila Najwa Nurisma

Vella Ananda

### Dokumentasi dan Video

Yuri Annisa Iqbal

Farah Rafiqah Aulia

### Editor

Kanya Putri Ayudia

Nasywa Nur Aisyah

### Writer

Angelia Pradinata

Najiba Gina Nurisma

Vindasya Almeira

Nabila Kanyaka Riyanto

### Design

Andrea Aretha Purnama

Jennyfer Febrina Wijaya

Karunia Hafifah Arifin

### Media Partner



**MEDIA**  
**AESCULAPIUS**



Special thanks to our  
**Sponsors**



# Today's Agenda

## Day 3 - Saturday, 6 September 2025

### Time

07:00 – 08:00	Registration	
08:00 – 08:30	Opening Ceremony	
08.30 – 09:00	Plenary Lecture 2 (ANMA) IBS and Probiotic	
09:00 – 10.15	Symposium 10 : IDDW Precision Oncology in Metastatic Colorectal Cancer	Symposium 11 : ANMA Esophageal Motility Disorder
10.15 – 11.30	Symposium 12 : IDDW Role of Probiotics in GI Disorders	Symposium 13 : ANMA Integrative Approaches in the Management of DGBI
11.30 – 13.00	Lunch & Visit Exhibition	
13.00 – 14.15	Symposium 14 : IDDW Advancing Gastrointestinal Therapeutics: Optimizing Management of IBD and GERD	Symposium 15 : ANMA Anorectal & Constipation Disorder
14.15 – 15.30	Symposium 16 : IDDW Strategic Approach to Acid- Related Disease: Customized Therapy Selection for Complex Clinical Profiles	Symposium 17 : ANMA Obesity & GI Motility
15.30 – 16.00	Special Lecture 3: IDDW Transforming Gastroenterology Practice: Harnessing Artificial Intelligence for Precision Diagnosis and Therapeutic Insights <small>Insights to</small>	Symposium 9 : ANMA Leaky Gut
16.00 – 17.00	Poster Winner Announcement & Closing Ceremony	





# Poster and Oral Presentation

Apart from symposium and workshop, IDWW ANMA 2025 also conducted poster and oral presentation competitions, with each competition held at a different location within the same venue. A total of 30 posters were showcased, representing a diverse array of research topics. Each poster included supplementary materials such as charts, graphs, and illustrative figures, which are typically displayed to facilitate discussion and engagement.

Meanwhile, the oral presentations commenced at 09:00 AM in Mutiara 12 Room, featuring 13 presenters from various countries: Indonesia, South Korea, Japan, China, and Vietnam. Of these, eleven presented in person, while two participated virtually via Zoom. Each presented studies were thoroughly evaluated by **Prof. Yeong Yeh Lee MD PhD**, **Prof. Marcellus Simadibrata MD, PhD**, and **Prof. I.D.N Wibawa, MD, PhD**, who assessed everything from the study design to the conclusion drawn. The research topics covered a range of areas, including new drug developments, surgical interventions, and stent application.

Meanwhile, the poster session held at the prefunction covered a wide range of neurogastroenterology topics. Aspects of effectiveness, efficacy, and considerations were presented in the form of case reports, systematic reviews, and meta-analyses.

## Sekretariat

The Indonesian Society of Gastroenterology Office  
C/o Menteng Square Apartment, Tower A No. AR06  
Jl. Matraman Raya No. 30E  
Jakarta 10430 – Indonesia

+62 21 29614303

iddwanma2025@gmail.com

@iddwanma2025

# Plenary Lecture 2

## IBS and Probiotics :

**Prof. Marcellus Simadibrata, MD, PhD and Gwee Kok Ann, MD, PhD**

The second Plenary Lecture was opened with a warm welcome from **Prof. Marcellus Simadibrata, MD, PhD** who served as the moderator. Prof. Marcellus then introduced the distinguished speaker, **Gwee Kok Ann, MD, PhD**, to share the latest insights on Irritable Bowel Syndrome (IBS) and the role of probiotics on preventing this gut-brain disorder.

Since perceptions of IBS have evolved, growing research provides strong evidence on the role of gut microenvironment in managing IBS. Post-infectious IBS, for instance, may disrupt the gut-microbiota, leading to increased intestinal permeability, immune activation, and neuromuscular sensitization of the gut, which may lead to dysbiosis. Conventional anti-inflammatory therapies have shown drawbacks such as inducing abdominal pain and acute constipation.



Recent studies show probiotics play a significant role in IBS management. It helps regulate immune response, strengthen the intestinal barriers, regulate melatonin, and reduce emotional reactivity, which means it not only addresses gastrointestinal disruption but also psychosomatic aspects of the disorder. In addition, Ann, MD, PhD, discussed recent updates on fecal microbiota transplantation (FMT), noting that despite its therapeutic aim of reshaping gut microbiota, FMT it is currently not recommended by the American College of Gastroenterology (ACG) due to inconsistent evidence and the heterogeneity of the microbiome.

# Symposiums

## **Symposium 10 IDDW: Precision Oncology in Metastatic Colorectal Cancer**

**Speaker: Hasan Maulahela, MD, PhD, Prof. Murdani Abdullah, MD, PhD, Prof. Aru Wisaksono Sudoyo, MD.**

The tenth IDDW 2025 Symposium on Precision Oncology in Metastatic Colorectal Cancer was opened by **Saskia Aziza Nusyirwan, MD**, as moderator. **Hasan Maulahela, MD, PhD**, presented Overview of Colorectal Cancer Diagnosis, highlighting that colorectal cancer (CRC) has become a health burden and ranks among the top three causes of cancer-related deaths in Indonesia. He underlined that CRC is a preventable disease, and that managing advanced colon cancer requires a more specific approach compared to other types of cancer.



Speaker in Symposium 10

**Prof. Murdani Abdullah, MD, PhD**, in his talk Role of Gastroenterologist in Sample Acquisition and Molecular Testing, emphasizes the critical role of proper sample handling to ensure diagnosis accuracy.

Among other samples, liquid biopsy enables earlier detection and provides more accurate diagnosis. He also adds that chemotherapy in CRC management is increasingly guided by molecular biomarkers, particularly microsatellite instability-high (MSI-H).

This point regarding the central role of biomarkers in guiding therapy was further reinforced by **Prof. Aru Wisaksono Sudoyo, MD** in Personalized Treatment with Immunotherapy Oncology in dMMR/MSI-H Metastatic Colorectal Cancer Patients. **Prof. Aru** highlighted how advances in biomolecular insights have transformed therapeutic decision-making, particularly in metastatic CRC. Tumors with similar histological appearances can harbour profoundly different genetic alterations, which dictate divergent therapeutic pathways. Both professors agreed that biomarkers have become central to guiding CRC therapy, marking a shift from conventional one-size-fits-all approach toward precision medicine.



### Symposium 11 ANMA: Esophageal Motility Disorder

**Speaker: Justin Wu, MD, PhD, Tadayuki Oshima, MD, PhD**

Following the recent ANMA symposium, this Esophageal Motility Disorder symposium highlighted the importance of precise diagnosis and treatment of esophageal motility disorder, taking into account each patient's pathophysiology to provide appropriate management. The session was moderated by **Sutep Gonlachanvit, MD, PhD**, from Thailand, and **M. Begawan Bestari, MD, PhD**, from Indonesia.

The session started with a fruitful discussion on Update on Achalasia and Motility Disorders. **Justin Wu, MD, PhD** highlighted important aspects of Esophagogastric Junction Outflow Obstruction (EGJO) management, a current trending esophageal issue, which requires specific attention and can be treated using Peroral Endoscopic Myotomy (POEM), a novel minimally invasive procedure.



QnA session with participants to speakers in Symposium 11

The second session, presenting an update on Esophageal Function Test delivered by **Tadayuki Oshima, MD, PhD**, stressed the importance of evaluating both supine and upright positions and incorporating additional manometric maneuvers,



Speaker in Symposium 11

including Multiple Rapid Swallows (MRS) and Rapid Drink Challenge (RCD), into the updated standardized protocols.

It was followed by the third session titled Unraveling Globus Sensation: Comprehensive Approaches to Diagnosis and Management presented by **Uday C Ghosal, MD, PhD** reminded us that this issue requires establishment on comprehensive protocols, as this symptoms often-overlooked symptom and the guidelines for its assessment and management remain limited.

### Symposium 12 IDDW: The Role of Probiotics in GI Disorders

**Speaker:**

The twelfth symposium of IIDW 2025 in The Role of Probiotic for Adult GI Disorders was opened by **Saskia Aziza Nusyirwan, MD** as moderator, and was followed by a hybrid presentation of Latest Findings on the Use of Probiotics for Irritable Bowel Syndrome by **Prof. Robert Jan Brummer, MD, PhD**. He emphasized the role of probiotics in Disorder of Gut-Brain Interaction (DGBI), reflecting the complex bidirectional communication between the gut and brain.

Microbes, barrier function, inflammation, serotonin, stress, and mental health are all interrelated, forming the foundation for the therapeutic potential of probiotics, although the exact site of interaction remains uncertain. **Prof. Robert** also highlighted that repeated switching of probiotic formulations should be avoided for at least 8–10 weeks.



The panel of speakers in Symposium 12

The session then continued on Latest Findings on the Use of Probiotics for Irritable Bowel Syndrome delivered by **Prof. Ari Fahrial Syam, MD, PhD**, who emphasized that probiotic uses poses emerging challenges in managing DGBI due to individual gut microbiota differences. Probiotics potentially alleviate Irritable Bowel Syndrome (IBS) symptoms. Prof. Ari also reflected on the complexity of IBS due to overlapping symptoms and emphasized that a thorough evaluation of clinical manifestations along with histopathological examination, is essential for accurate assessment and differential diagnosis.

### Symposium 13 ANMA: Integrative Approaches in the Management of DGBI

**Speaker: Gengqing (Gavin) Song, MD, PhD, Ching-Liang Lu, MD, PhD, Andrew Seng Boon Chua, MD, PhD**

The session on Integrative Approaches in the Management of DGBI was moderated by **Prof. M. Masudur Rahman, MD**, from Bangladesh, and **Kaka Renaldi, MD, PhD**, from Indonesia. In the first session, **Gengqing (Gavin) Song, MD, PhD**, delivered a lecture on Transcutaneous Neuromodulation for Gastrointestinal Motility Disorder. He emphasized that conventional medical therapy for gastrointestinal motility disorders often shows limited efficacy, as improving motility alone does not necessarily alleviate symptoms. He compared Transcutaneous Electrical Stimulation (TES) with Transcutaneous Electrical Acustimulation (TEA), noting their potential roles in neuromodulation-based therapy.



The panel of speakers in Symposium 13

The second session, **Ching-Liang Lu, MD, PhD**, presented Diet Therapy and IBS. Food consumption could exacerbate symptoms, as growing research shows 10% increase in ultraprocessed food (UPF) intake increases the risk to develop IBS by up to 8%. The low-FODMAP diet, introduced in Taiwan, is one of the most promising non-pharmacological results to address this issue.

This approach aims to eliminate lactose-containing dairy, followed by reintroduction to evaluate triggers and create personalized FODMAP diet. He also emphasises the importance of bringing this approach as first-line treatment before medications.

In the final session, **Andrew Seng Boon Chua, MD, PhD**, presented Integrating Dietary and Behavioral Therapies in the Management of Chronic Constipation. He promoted integrative approaches, including behavioural management, fiber-based diet, and exercise therapy to accelerate intestinal transit time. Neuromodulation such as acupuncture, electroacupuncture, and cranial electrotherapy, can also be combined with behavioral therapies to reduce psychological distress and improve quality of life.

**Symposium 14 IDDW: Advancing Gastrointestinal Therapeutics: Optimizing Management of IBD and GERD**

**Speaker: Prof. Muhammad Miftahusurrur, MD, PhD, Prof. Dadang Makmun, MD, PhD**

The fourteenth IIDW 2025 Symposium in Advancing Gastrointestinal Therapeutics: Optimizing Management of IBD and GERD was moderated by **Achmad Fauzi, MD**.

The first session, Advancing IBD Care: The Role Vedolizumab in Clinical Practice, was delivered by **Prof. Muhammad Miftahusurrur, MD, PhD**. The discussion emphasised that STRIDE II serves as a recommendation to determine therapeutic goals within the treat-to-target strategy for IBD management. Therapeutic options for moderate to severe IBD include biologic agents such as anti-TNF $\alpha$  and anti-integrin,



Speaker in Symposium 14

while newer agents like Vedolizumab offer additional advantages, including higher rates of remissions, and improved mucosal healing.

The second session continued with the topic GERD: Old Disease with New Approach PCAB is the New Era of GERD Treatment, is it Better Than PPI? presented by **Prof. Dadang Makmun, MD, PhD**. The session highlighted that GERD is a physiological phenomenon rather than a "one-size-fits-all" disease. Symptoms arise through multiple mechanisms, varying in each patient, making standardized algorithms useful only as broad guidance rather than strict rules.

Although PPIs remain the mainstay of GERD therapy, 40–55% of patients continue to experience refractory symptoms. This opened the door to newer options, particularly P-CABs, which provide faster, stronger, and more sustained suppression. **Prof. Dadang** concluded that P-CABs may herald a new era of GERD management, especially for patients unresponsive to PPIs.



### **Symposium 15 ANMA: Anorectal & Constipation Disorder**

**Speaker: Syifa Mustika, MD, PhD, Marcellus Simadibrata, MD, PhD, Tanisa Patcharatrakul, MD, PhD**

After lunch break, ANMA symposium was continued with Symposium 15 on Anorectal and Constipation Disorder, moderated by **Xiao Hua Hou, MD, PhD**, from China, and **Rabbinu Rangga Pribadi, MD**, from Indonesia. In the first session, **Syifa Mustika, MD, PhD** emphasized a comprehensive approach in addressing Fecal Incontinence (FI) and highlighting the role of structured severity scoring systems, digital rectal examination with DRESS scoring, and advanced imaging modalities such as endoanal ultrasound and defecography. Management should follow European guidelines, starting with first line treatment and lifestyle modification then progressing to second-line interventions, including sacral nerve modulation.



The panel of speakers in Symposium 15

**Marcellus Simadibrata, MD, PhD** discussed Triple Action on Chronic Constipation, noting its high prevalence and significant socioeconomic burden. Up to 50% patients remain dissatisfied with conventional laxatives, thus highlighting the need for integrative and patient-centered therapy.

Elobixibat was highlighted as an effective option to significantly improve constipation symptoms and raise patient satisfaction.

In the final session, **Tanisa Patcharatrakul, MD, PhD** discussed Dyssynergic Defecation, addressing challenges in accessibility and poor compliance with biofeedback therapy. **Patcharakul, MD, PhD** also introduced novel home-based biofeedback therapy approaches to enhance long-term outcomes.

### **Symposium 16 IDDW: Strategic Approach to Acid-Related Disease: Customized Therapy Selection for Complex Clinical Profiles**

**Speaker: Prof. Ari Fahrial Syam, MD, PhD, Prof. Muhammad Miftahussurur, MD, PhD.**

The sixteenth symposium of IIDW 2025, moderated by **Hasan Maulahela, MD, PhD**, on Strategic Approach to Acid-Related Disease: Customized Therapy Selection for Complex Clinical Profiles, featured two insightful presentations on updates of therapeutic advances. **Prof. Ari Fahrial Syam, MD, PhD** discussed Gastric Acid Secretion and Motility: The Role of Tegoprazan. He highlighted the emerging role of Tegoprazan as a potent alternative to traditional PPIs, emphasizing its rapid onset, sustained acid suppression, and potential clinical benefits for patients with gastric acid-related disorders.



Prof. Ari Fahrial Syam, MD, PhD as speaker in Symposium 16

Beyond its pharmacological efficacy, Tegopran demonstrates clinical relevance in improving therapeutic outcomes, particularly in cases where conventional PPIs fall short.

Complementing this, the next topic on Integrative Management of Acid-Related Diseases in Patients with Multifactorial Health Concerns was delivered by **Prof. Muhammad Miftahussurur, MD, PhD**. He underlined that refractory GERD in diabetic patients can be managed with Esomeprazole, which maintains gastric pH >4, while Tegopran provides effective relief for nighttime heartburn. **Prof. Miftahussurur** noted that Esomeprazole remains the only PPI safe for cirrhotic patients with CTP grade C, whereas Tegopran shows lower hepatotoxicity and fewer drug interactions, particularly with Atorvastatin. He further noticed that long-term and high-dose PPI use may increase the risk of chronic kidney disease, warranting careful consideration.

#### **Symposium 17 ANMA: Obesity & GI Motility**

**Speaker: Yeong Yeh Lee, MD, PhD, Tri Juli Edi Tarigan, MD, PhD, Hiroto Miwa, MD, PhD**

Moderated by **Uday C. Ghosal, MD, PhD**, from India, and Fardah Akil, MD, from Indonesia this symposium on Obesity & GI Motility highlighted the multifaceted impact of obesity on gastrointestinal (GI) motility, reinforcing both emerging evidence and clinical implications.

The first session, Obesity and GERD, was delivered by **Yeong Yeh Lee, MD, PhD**, who highlighted obesity as a major risk factor not only for gastroesophageal reflux disease (GERD) but also for GI cancers.



The panel of speakers in Symposium 17

**Lee, MD, PhD** noted that obesity doubles the risk of GERD and the risk of GI cancers by 1.5 times. Consensus statements in Southeast Asia describe GERD as typically mild to moderate, with transient hiatus herniation and postprandial reflux recognized as key mechanisms. Weight management remains as the first-line strategy.

**Tri Juli Edi Tarigan, MD, PhD** opened the second discussion on the topic: GERD management in Prediabetes. He explained delayed gastric emptying and impaired motility contribute to reflux, and that diabetic gastroparesis and enteropathy require early recognition at the prediabetes stage. Lifestyle modification with dietary fiber, exercise, and microbiota-targeted approaches was emphasized before pharmacotherapy.

The final session, Diet and GERD Microbiota in Obesity: Impact of Obesity, was presented by **Hiroto Miwa, MD, PhD**. He showcased evidence linking obesity to altered esophageal microbiota and inflammation-driven dysbiosis, while underscoring the protective role of dietary fiber for both GERD and obesity through microbiota modulation.

**Symposium 18 ANMA**

**Speaker: Kwang Jae Lee, MD, PhD, Putut Bayupurnama, MD, Hyojin Park, MD, PhD**

The final ANMA symposium, moderated by **Hiroto Miwa, MD, PhD**, from Japan, and **Dadang Makmun, MD, PhD**, from Indonesia, explored the evolving concept of leaky gut, highlighting its pathophysiological basis and clinical relevance across gastrointestinal disorders.

**Kwang Jae Lee, MD, PhD**, opened the first session with Gastric Disorder and Leaky Gut, explaining how epithelial barrier dysfunction allows harmful substances to cross the mucosa, triggering immune response and inflammation. He also emphasized the common gastrointestinal (GI) symptoms, such as dyspepsia, can further impair barrier integrity.



Speaker in Symposium 14

The second session, delivered by **Putut Bayupurnama, MD**, titled Intestinal Permeability, Leaky Gut, and Intestinal Disorders, discussed how defects in intestinal permeability contribute to early manifestations of GI and systemic diseases, including celiac disease, inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS). He underscored the importance of short-chain fatty acids (SCFAs) in preserving epithelial integrity.

In the final session, **Hyojin Park, MD, PhD**, presented Drug Repositioning for Impaired Gut Permeability. He noted that postoperative ileus (POI) involves dysbiosis, inflammation, and barrier disruption, and suggested probiotics as a mitigation strategy. He also identified macrophages and mast cells as key inflammatory mediators and proposed them as promising therapeutic targets.

## Special Lectures

### **Special Lecture 3 IDDW: Transforming Gastroenterology Practice: Harnessing Artificial Intelligence for Precision Diagnosis and Therapeutic Insight in GI**

**Speaker: Hasan Maulahela, MD, PhD**

The third special lecture of IDDW was delivered by **Hasan Maulahela, MD, PhD**, and moderated by **Virly Nanda Muzelina, MD**, on Transforming Gastroenterology Practice: Harnessing Artificial Intelligence for Precision Diagnosis and Therapeutic Insight in GI. In this session, **Hasan, MD, PhD**, highlighted the emerging role of artificial intelligence (AI) in gastroenterology, particularly in Barrett's esophagus.

#### Sekretariat

The Indonesian Society of Gastroenterology Office  
C/o Menteng Square Apartment, Tower A No. AR06  
Jl. Matraman Raya No. 30E  
Jakarta 10430 – Indonesia

+62 21 29614303

iddwanma2025@gmail.com

@iddwanma2025





AI has the ability to detect suspicious areas and provide real-time alert signals during endoscopic procedures, supporting early recognition of potential lesions. Nevertheless, its use still faces important limitations, as most current studies are single-centered with relatively small sample sizes, making external validity and generalizability still insufficient. Larger multicenter studies and local validation are essential to ensure reliable clinical application.

Beyond Barrett's esophagus, AI has potential applications in the screening, diagnosis, and management of various conditions, including *H. pylori* infection,

precancerous lesions, polyps, and inflammatory bowel disease (IBD), extending its utility to lower endoscopy. Overall, Hasan, MD, PhD, highlighted that AI has the ability to enhance diagnostic accuracy, streamline workflow, and enable more personal care. However, Hasan, MD, PhD, mentioned structured clinical adoption, ethical oversight, and robust validation remain essential before AI can be fully integrated into routine gastroenterology practice.



The speaker and moderator in Special Lecture 3



The speaker and moderator in Special Lecture 4

### ***Special Lecture 4 IDDW: Comprehensive Assessment of Gut Health Through Microbiota Profiling and Metabolite Analysis***

**Speaker: Rabbinu Rangga Pribadi, MD**

The fourth special lecture of IDDW titled Comprehensive Assessment of Gut Health Through Microbiota Profiling and Metabolite Analysis, was delivered by **Rabbinu Rangga Pribadi, MD** and moderated by **Triyanta Yuli Pramana, MD**. The session focused on the influence of diet on gut microbiota, comparing Western, vegetarian, Mediterranean, and ketogenic diets. They also highlighted gut microbiota analysis, which involves bacterial profiling and metabolite assessment, particularly short-chain fatty acid (SCFA). **Rabbinu, MD** highlighted the complexity of assessing gut health. Profiling gut microbiota and metabolites provide insight into diversity, dietary influences, and metabolite levels. While current applications remain primarily research-based, they can also help patients understand how diet affects gut conditions. Further approach, there is significant potential for diagnostic and therapeutic applications, particularly in inflammatory bowel disease (IBD) and colorectal cancer.

# ***What Do The Participants Say?***

## **Zahraa Sh. Hmood, MD**

Zahraa Sh. Hmood, MD, from Tongji Medical Technology, China, shared that this was her first visit to Indonesia. Inspired by global health issues, she chose to pursue gastroenterology to improve people's health. She praised the event's organization for valuable knowledge exchange and highlighted their gastric bypass stent innovation.

## **Prof. Shaman Rajindrajith, MD, PhD**

Prof. Shaman Rajindrajith, MD, PhD, professor of pediatric medicine at the University of Colombo, Sri Lanka, noted that his motivation in gastroenterology is to improve the quality of life of affected children and prevent long-term consequences. He found the symposium valuable for learning about the latest developments in the field and their application in pediatric medicine.

## **Prof. Marcellus Simadibrata, MD, PhD**

Prof. Marcellus Simadibrata, MD, PhD, serving as one of the distinguished faculty members, shared his impressions after serving as a judge in the oral presentation session. He commended the participants' outstanding research while emphasizing gastroenterology research still has room for growth. He expressed hope that many doctors will be attracted to research in the future.

### **Sekretariat**

The Indonesian Society of Gastroenterology Office  
C/o Menteng Square Apartment, Tower A No. AR06  
Jl. Matraman Raya No. 30E  
Jakarta 10430 – Indonesia

+62 21 29614303

iddwanma2025@gmail.com

@iddwanma2025







**Pictures of Day 3**  
**IDDW ANMA 2025**





# Winner Announcement

Indonesia Digestive Disease Week (IDDW) 2025 concluded with the announcement of poster and oral presentation winners.

In the poster session, the first place of case report category was awarded to **Igna Eddy Adnyana, MD from University of Indonesia, Cipto Mngunkusumo Hospital**, for Challenges in the Diagnosis and Management of Thrombosis in Acute Severe Ulcerative Colitis. Second place in the case report category went to **Amal Arifi Hidayat, MD, from Universitas Airlangga, Dr. Soetomo General Academic Hospital**, for Navigating Gastroparesis Diagnosis in Resource Limited Setting: An Electrogastrography-Based Case Report.

In the research category, first place was granted to **Muhammad Riadi Dwisaputro, MD, from Universitas Gadjah Mada**, with Artificial Intelligence as a Game Changer in Esophagogastroduodenoscopy: A Systematic Review and Meta-Analysis. The second place was awarded to Bryanandda, MD, from Sanjiwani General Hospital, for Effectiveness of P-CAB Based Therapy for Helicobacter pylori Eradication in Peptic Ulcers Disease: A Meta-Analysis.

For the oral presentation, both winners were from **Juntendo University**. The first place was granted to **Tsutomu Takeda, MD**, for Characteristic of Colonic Wall Motility in Functional Constipation: A Cine MRI-Based Comparison with Healthy Subjects, while second place was secured by **Mariko Hojo, MD**, with her work Cost-Utility Analysis of Treatment Strategy for Chronic Constipation in Japan.

**Congratulations to all winners for their outstanding contributions and exceptional research achievements!**



## Sekretariat

The Indonesian Society of Gastroenterology Office  
C/o Menteng Square Apartment, Tower A No. AR06  
Jl. Matraman Raya No. 30E  
Jakarta 10430 – Indonesia

+62 21 29614303

iddwanma2025@gmail.com

@iddwanma2025





+62 857 1002 559 (Maryam) | +62 896 7766 7764 (Nisa) | +62 857 1842 9590 (Tria)

iddwanma2025@gmail.com

@iddwanma2025 | @pbpgi\_lsg

